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Purpose: Adjuvant endocrine therapy (ET) can reduce the risk of recurrence among females with 
hormone receptor-positive breast cancer. Overall, initiation and adherence to ET are suboptimal, 
though reasons are not well described. The study’s objective was to better understand ET deci-
sion making, prescribing, and patient management from oncology providers’ perspectives.
Methods: Using purposive sampling, we recruited oncology providers who saw five or more 
breast cancer patients per week (n=20). We conducted 30–45-minute telephone interviews, using 
a semistructured guide to elicit perspectives on ET use. We used thematic content analysis to 
systematically identify categories of meaning and double-coded transcripts using Atlas.ti.
Results: Providers recommend ET to all eligible patients except those with contraindications 
or other risk factors. Providers base their ET prescribing decisions on the patient’s menopausal 
status, side effects, and comorbidities. ET is typically discussed multiple times: at the onset of 
breast cancer treatment and in more detail after other treatment completion. Providers felt that 
the associated recurrence risk reduction is the most compelling argument for patients during ET 
decision making. While providers rarely perceived noninitiation as a problem, nonadherence 
was prevalent, often due to unresolvable side effects.
Conclusion: From the clinicians’ perspectives, side effects from ET are the dominant factor in 
nonadherence. Efforts to improve adherence should focus on strategies to minimize side effects 
and ensure clinicians and patients are well informed regarding optimal side effect management. 
This finding has important implications for novel endocrine regimens that offer improved out-
comes through longer duration or more intensive therapy.
Keywords: breast cancer, endocrine therapy, oncology, oncologist, qualitative interviews
Introduction
Endocrine therapy (ET) is an important part of treatment for females with hormone 
receptor-positive (HR+) breast cancers. Both forms of ET, tamoxifen and aromatase 
inhibitors (AI), have been shown to reduce in-breast recurrence by ~40% and 
breast cancer mortality by a third when taken as recommended for at least 5 years.1 
Unfortunately, up to half of clinically eligible females fail to initiate ET and of those 
who do initiate, approximately a quarter are nonadherent and another quarter have 
discontinued by 5 years.2 The reasons for underuse of ET are multifaceted and likely 
driven by oncology providers’ prescribing and management patterns, as well as 
individual patients’ motivation and self-efficacy to continue taking an oral medication 
that is known to cause burdensome side effects.3–5 The most commonly reported side 
effects to ET are hot flashes and night sweats (associated primarily with tamoxifen), 
bone loss, and joint and muscle pain (associated primarily with AIs).6
In a systematic review, interpersonal characteristics associated with optimal ET 
initiation and adherence included: provider referral and recommendation, quality 
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of patient–provider communication, and social support.2 
Patients who reported seeing a medical oncologist, receiv-
ing patient-centered care, valuing their provider’s opinion, 
having high self-efficacy in communications with their 
provider(s), and receiving enough information about ET from 
their provider(s) were more likely to be adherent and persis-
tent with ET, whereas other factors commonly assumed to 
be related to medication nonadherence, such as frequency of 
office visits, patient education and financial stability, urban/
rural residence, and size of the treating facility, were not 
significant predictors of ET use.2 These findings suggest that 
the quality of the patient–provider relationship may provide 
clues as to whether patients will take ET as prescribed for 
the full duration of treatment, and how providers can best 
support patients during this phase of care.
Oncology care providers play an important role in 
prescribing ET, preparing patients for side effects and other 
difficulties they may encounter while taking ET, and manag-
ing side effects and medication changes over time. They also 
play a part in directing patients to resources for support and 
counseling about ET, motivating patients to continue taking 
ET as prescribed, and communicating with patients and their 
primary care providers about the appropriate duration and 
continued management of ET use.7,8 With new evidence sug-
gesting that longer duration of ET or more intensive therapy 
may be warranted in some cases,9,10 more attention should 
be paid to oncology providers’ roles in optimizing ET use 
to prevent breast cancer recurrence, ensure high quality of 
life, and reduce breast cancer-related death. In this study, we 
sought to contribute to the existing literature on ET use by 
soliciting oncology providers’ perspectives on the prescribing 
and management of ET in their breast cancer patient popula-
tions. Rarely has the provider’s voice been incorporated in 
studies focused upon oral oncology medication adherence. 
However, adding these important players’ perspectives to 
the ET discussion may provide insight into the processes of 
care around ET initiation and longer term use, the realities 
and challenges associated with supporting patients taking ET, 
and strategies used by providers to prepare patients for – and 
help to manage – side effects in practice.
Methods
Twenty in-depth telephone interviews were conducted with 
oncologists, surgeons, physicians’ assistants, and oncology 
nurses as part of a larger patient and provider qualitative 
research study on the barriers and facilitators to ET use. Using 
purposive sampling, we identified 20 oncology providers. 
Most were identified through the North Carolina Oncology 
Association Web site (http://ncoa-northcarolina.com/) and 
through contacts with clinical partners. We emailed and 
faxed a recruitment flyer to potentially eligible providers, 
and interested providers contacted the study team in order 
to participate. Providers were eligible to participate in an 
interview if they saw five or more breast cancer patients per 
week. The majority of participants were based at two large 
academic medical centers and community-based practices 
across North Carolina.
Each interview lasted ~30–60 minutes and was conducted 
by a professional moderator using a semistructured discussion 
guide to allow for a deeper exploration of the topics under 
investigation. The overall objective of the provider inter-
views was to better understand providers’ perceptions and 
experiences regarding prescribing and managing ET among 
their HR+ breast cancer patients. These interviews asked 
specific questions in order to: 1) Understand when and how 
providers first introduce the concept of ET to their patients; 
2) Understand providers’ perceptions about the best and most 
compelling approach for presenting the idea of ET to patients; 
3) Learn more about how providers decide which ET to pre-
scribe and for how long; 4) Assess how much of a problem 
providers perceive noninitiation to be among eligible patients 
and the reasons some refuse ET at the outset; 5) Assess how 
much of a problem nonadherence is among eligible patients 
and identify the reasons for nonadherence; and 6) Understand 
strategies employed by providers to support ET use.
All interviews were conducted by a professional inter-
viewer (DB) and a note-taker (MCR), neither of whom was 
involved with patient management or care. The interviewer 
and note-taker were familiar with research about breast 
cancer, ET, and clinical guidelines for ET use among eligible 
patients. Interviews were digitally recorded, professionally 
transcribed, de-identified, and transferred to Atlas.ti for 
analysis. Members of the study team (SBW, MCR, KRH, 
and DB) first reviewed all transcripts and created an initial 
concept code list. We used thematic content analysis to iden-
tify categories of meaning. Response patterns, both within 
a particular question or concept and between concepts, 
were explored. These concept codes were systematically 
discussed and defined clearly, with exemplar codes as well 
as exclusions made explicit to facilitate coding and ensure 
consistent application of codes across transcripts and coders. 
Two authors (DB, MCR) then coded the first 25% (five) of 
provider transcripts and discussed code application. Very 
few inconsistencies were identified in code application. 
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Any inconsistencies or overarching questions about code 
meaning were discussed and reconciled by the research 
team. The codebook was revised where applicable. Once 
consensus was reached on the first five transcripts, the 
remaining transcripts were coded individually by a single 
coder following a common final codebook (Table 1). 
As before, any questions about code meaning or application 
were addressed as they emerged with the second coder and 
lead investigator (SBW). This process ensured consistency, 
reliability, and reproducibility in our analytic coding pro-
cess. We achieved saturation of themes before completing 
the 20 interviews.
Table 1 Final codebook descriptions and exemplary quotes
Code Definition Exemplary quotes
Age-based decision making Description of how age influences  
prescribing behavior 
“i think when you’re dealing with the more elderly women, i think quality 
of life is a more prominent feature and wondering, not worrying so much 
about the quantity. But when you’re dealing with younger women, it’s much 
more focused on kind of getting rid of the cancer and keeping it gone forever. 
so, there’s sort of a shift depending on the age and just temperament of the 
patient.”
Beliefs in line  
with behavior
Discussion of how patients’ beliefs are 
concordant/discordant with  
medication behavior
“some of those patients just refuse to take anything. some of them are pretty 
happy with surgical therapy. You know, they have an operation, they cut it 
out, they think they’re cured and no matter how much data you talk to them 
they just don’t want to take a pill.”
comorbid conditions Discussion of the influence  
of comorbidities on medication 
behavior
“so, earlier this month i saw a younger woman with Dcis. And you would 
normally consider tamoxifen but she has a history of recurrent venous-
thrombo-embolic disease and i felt the chemo-prevention was outweighed by 
the risks of thrombo-embolic disease.”
compelling arguments includes responses to “what is the 
most compelling argument for eT 
initiation?”
“And so, i almost stand on top of my head to beg them, you know […] And 
the things that i’ll tell them is that sometimes you’ll get an 85-, 90-year-old 
female to come in and there’s cancer growing all up their chest and you can 
put them on an aromatase inhibitors if they’re er- or Pr-positive. And that’s 
not chemotherapy. And all the disease will go away within a few months’ 
time. so, i’ll give them these extreme examples to try to show ‘this is how 
important this is’.”
coping includes management strategies  
for reported patient side effects
“Well, with tamoxifen i try to stay away from any of the [antidepressants]  
that can have interference with tamoxifen metabolism. so, i tend to select  
Lexapro Effexor sometimes if the issue is more hot flashes than mood 
disorder. Then effexor can be helpful. […] And then some folks just have 
hot flashes primarily at nighttime. Sometimes we’ll try Neurontin. And then I 
usually talk to people about, you know, exercise. You know, there’s data out 
there for acupuncture if they’re inclined toward that type of intervention. And 
oftentimes they’ll just get better with time, so encouraging just sticking it out 
and let’s see if it gets better. Or just environmental changes, you know, ‘What 
do you wear at night? What kind of sheets do you put on? Do you have a fan 
in your room,’ you know, things like that.”
cost Discussion of cost as a barrier  
or facilitator for eT use
“But nowadays, you know, all of them come in generic. so, they’re a whole 
lot cheaper. But, see, in the years past they might have been $450 a month; 
Femara was.”
Double-edged sword Discussion of risks balanced 
with benefits
“i think most of them are weighing the wanting to get rid of the breast cancer. 
That’s probably their primary motivation. i think secondarily they’re thinking 
about issues of life expectancy and then i think it’s quality of life.”
Fear Perceived patients’ fears influence  
on medication behavior
“Most people, they’re more scared about their breast cancer and so they want 
to be on these drugs.”
Fertility Fertility as contraindicated to eT use “We refer them to fertility specialists. We have a clinic and they go over the 
issues too. And i’ve had a handful of people who’ve gone off tamoxifen and 
gotten pregnant.”
information seeking includes discussion of informational 
materials that providers use, including 
verbal, audio, and visual materials
“i think they use, patients tell me – i don’t know if they’re called ‘chat rooms’ 
or online, you know, kind of forums where people talk about their breast 
cancer diagnosis and their treatment. Patients get a lot of information from 
other breast cancer patients.”
(Continued)
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Table 1 (Continued)
Code Definition Exemplary quotes
informational materials information that providers provide to 
improve adherence (eg, information 
from a study or a trial)
“We sit them and explain it but they get educational materials too. Anything 
that you can give for visual stimulation and also auditory. You know, 
sometimes i think it’s good to have a tape recording of your teaching of it and 
then they can listen to that tape recording again.”
interventions intervention opportunities that 
providers use to get patients to 
initiate/adhere to eT
“We run a clinical trial in the office where they can sign for this clinical trial 
where they’ll get text messages to remind them every day or i will set up their 
iPhone for a daily reminder, you know, if they have that.”
Provider frustrations Provider-reported challenges for 
influencing patient adherence
“We have a lot of alternative people … And they have such a mindset on the 
alternative medications that they won’t pick up what regular medicine does. 
And you try to teach the fool out of it. But this is few and far between.”
no-brainer Discussion of the “obvious choice” 
of eT
“Most are pretty on board with it. i think, most (wouldn’t you?), when we’re 
talking about invasive cancer, i think most are scared of their breast cancer, 
and understandably so. so, i think most are willing to give a pill a try.”
Perceived (non) adherence Discussion of how big of a problem 
nonadherence/persistence may be 
for their patients
“i would give you a guess [of nonadherence] would be 15%–20%.”
Perceived (non) initiation Discussion of how big of a problem 
noninitiation may be for their patients
“every once in a while you’ll have somebody like that [noninitiator]. You 
know, i’m just talking about a very, very small population.”
Perceived reasons  
for (non) adherence
Provider-perceived reasons for 
nonadherence/persistence among 
patients
“i’ve even had people skip it for long plane rides and things. so, i can’t come 
down too hard. But i do say ‘look, in general it’s best to take all that’.”
Perceived reasons  
for (non) initiation
Provider-perceived reasons for 
noninitiation among patients
“[some women are] looking at herbal things. And they don’t like taking regular 
medications. And so, sometimes they’re so holistic and so out there, you 
know, that they don’t want to pick up a medication [eT] like that.”
Prescribing decision making includes which patients get what/
when, contraindications
“Postmenopausal, we generally go with the orals and it’s usually based on 
(several?) studies. So, most of our patients will be offered Arimidex first, since 
it was first and then depending on tolerance, they might get – in terms of an 
adjuvant setting, they might get switched over to one of the other hormonal 
therapies if they didn’t tolerate Arimidex.”
Provider dismissiveness Dismissing side effects and 
concerns of patients, discussion of 
misattribution of side effects with eT 
among patients
“And, admittedly, there is a population of folks out there who – you know, 
i don’t want to in any way belittle their side effects but i think there’s a 
population who are looking for some sort of side effect to attribute to the 
medication as an excuse not to take it.”
Provider risk 
communication
includes discussion of risk perception, 
risk of side effects, and cancer  
risk scores
“Usually you can sort of like draw a scale and say ‘OK, here’s the one thousandth 
chance that you’re going to get uterine cancer from tamoxifen if that’s what you’re 
worried about. here’s, on the other side, your chance of dying from breast cancer 
will be changed by 100–1,000.’ so i say ‘Well, would you rather have $100 or one 
dollar? Which is more?’ And i’ll say ‘Well, then, this is what you want to do.’ And 
there’s usually some way you can get through and make sense of it.”
rare complications Discussion of rare complications  
to eT
“We know there’s endometrial cancer, blood clots.”
reminders Discussion of risk of side effects “i tell them to put it in a place so that when they do their repetitive daily 
action, such as brushing their teeth or blow drying their hair or showering or 
whatever, they will see it and take it. Or use a pill box with Monday through 
Friday kind of thing.”
research gap  
and recommendations
Perceived research gaps  
and recommendations
“i guess the only thing that i’m hopeful for, and i think there are some studies 
ongoing, are trying to understand who we can predict to be the patients who 
are going to be poorly tolerant of the aromatase inhibitors; either clinical factors 
or even, you know, sniff analysis and pharmaco-genomic studies will really help 
us, our pharmaco-genomic studies will really help us understand who may be 
less tolerant so we can go ahead and start intervention programs ahead of time.”
risk of recurrence Discussion of risk of recurrence “You can calculate the risk of recurrence. The words ‘high,’ ‘low risk,’ you 
know, mean many different things.”
risk of side effects Discussion of risk of side effects “You know, most people want to know what the side effects and risks are.”
shared decision making Description of shared  
decision-making process around eT
“i mean i think modern breast cancer therapy is very much a collaborative 
doctor–patient situation for most of us. i mean, you know, i think it’s pretty 
rare for somebody to sort of give me the impression that she wanted to go 
ahead and proceed with therapy, take the prescription and then not do it.”
(Continued)
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Table 1 (Continued)
Code Definition Exemplary quotes
side effects: cognition Description of patient report of 
cognitive side effects, includes things 
such as cognitive lapses, due to eT
“i’ve had a few patients that they feel like they’re […] in a fog.”
side effects: cosmetic Description of patient experiences 
with hair loss and other cosmetic 
issues due to eT
“i would say cosmetic symptoms … changes in hair pattern. Those are always 
disturbing.”
Side effects: hot flashes Description of experiences with hot 
flashes due to ET
“So, for the tamoxifen, you know, for the younger women, hot flashes is 
probably the number one.”
side effects: joint/bone pain Description of experiences with  
joint/bone due to eT; also includes 
leg cramps
“so, they tend to have more trouble. And then the joint pains is the other 
main symptomatic issue. And the classic, from my reading of the literature and 
my experience, what i think is the classic is the hand, you know, swelling and 
pain, stiffness in the hands.”
side effects: mood Description of experiences with 
mood swings/mental health issues 
associated by patients with eT;  
also includes leg cramps
“so, and actually mood disturbance too, you know, feeling irritable. i think that 
probably is real to some extent for some folks.”
side effects: other Discussion of other side effects 
attributed by patients to eT
“i’ve had a few patients that they feel like they’re nauseous while taking the 
medicine.”
side effects: overwhelming instances when patients explicitly 
discuss side effects as “overwhelming” 
or quit eT because the side effects 
are overwhelming
“Other patients have tried it for a brief period of time and just felt like they 
don’t tolerate it. They have joint aches and pains that are just unbearable and 
tamoxifen wouldn’t be an option for them due to previous clotting or stroke 
history after trying all the Ais.”
side effects: sexual function Description of patient experiences 
with sexual function due to eT
“no. it’s more about – the other big issue on both of them is obviously loss 
of libido, vaginal dryness, lack of interest, and then how to deal with that. 
so, i generally have a sexuality conversation with all the patients and ask them 
how that’s going and if they’re having any symptoms or any problems.”
side effects: weight gain Description of patient experiences 
with weight gain due to eT
“sometimes we’ll see some weight gain. The literature doesn’t suggest that 
they’re going to have weight gain, but I definitely see it.”
Abbreviations: Ais, aromatase inhibitors; eT, endocrine therapy; Dcis, ductal carcinoma in situ; er, estrogen receptor; Pr, progesterone receptor.
Verbal informed consent was obtained from all individual 
participants included in the study. This study was approved 
by the University of North Carolina at Chapel Hill Institu-
tional Review Board.
Results
Oncology providers who were interviewed were primarily 
medical doctors (70%), although 20% were nurse practi-
tioners, and 10% were physician assistants (Table 2). The 
average age of providers interviewed was 48 years, with an 
average of 17.3 years since their medical training. Provid-
ers reported seeing ~33 breast cancer patients per week, 
and reported that just over two-thirds of their practices were 
breast cancer patients. We would expect approximately three-
quarters of these patients to be HR+ and eligible for ET.11 
Most practiced in a suburban (55%) or urban (40%) setting, 
whereas only 5% practiced in a rural setting. Just over half 
reported practicing in an academic medical center.
The salience of specific codes, in terms of both over-
all frequency of mention and the proportion of provid-
ers who mentioned each code, is reported in Table 3. 
For example, 95% or more of providers mentioned 
the following in their interviews: coping strategies; perceived 
noninitiation; perceived nonadherence; perceived reasons for 
nonadherence; prescribing decision making; provider risk 
communication; hot flashes; and joint pain. These topics were 
among the most frequently mentioned codes across all tran-
scripts. In the following pages, the overarching themes from 
Table 2 Descriptive characteristics of oncology providers 
interviewed
Characteristics Mean, %
Age (years) 47.8
Provider role (%)  
Medical doctor 70.0
nurse practitioner 20.0
Physicians assistant 10.0
Years since training 17.3
Patient mix (% breast cancer patients) 68.0
Patient load (per week) 32.9
Practice setting (%)  
Urban 40.0
rural 5.0
suburban 55.0
Academic (vs nonacademic) (%) 55.0
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these in-depth interviews, as well as illustrative verbatim 
quotes, are presented (see “Methods” section).
Providers recommend eT to virtually all 
eligible patients except those with medical 
contraindications, significant comorbidities, 
or other serious risk factors
According to the providers interviewed, the majority of their 
breast cancer patients (~70%) are estrogen or progesterone 
receptor-positive. Providers recommended ET to virtually all of 
their HR+ patients except in the rare instances of medical con-
traindications. Some of the providers described it this way:
The majority of those I see who are hormone receptor-positive 
are going to be on some kind of endocrine therapy … 
[I always recommend it] because it’s safer than aspirin.
I would say that maybe once or twice a year, [I might 
not recommend ET] to somebody who had a compelling 
reason to be on ET but who had risk factors from both 
the AI and Tamoxifen that outweighed the benefits. 
So imagine somebody who had a high enough risk of 
breast cancer that you wanted to give her ET, but she 
had already had three bone fractures from osteoporosis 
and a history of multiple blood clots. Essentially you’d 
have no options.
Physicians reported that they have the first conversation 
about ET with all eligible patients soon after diagnosis as 
part of the projected overall treatment plan. This way, ET 
will be viewed by the patients as the next step in – and an 
integral part of – the treatment regimen. Later, after the 
patient has had surgery and completed chemotherapy and/
or radiation therapy, the physicians discuss the intricacies of 
Table 3 salience of coded concepts in interview data
Code Code frequency % Providers who mentioned code
coping 94 100
Perceived (non) initiation 52 100
Perceived reasons for (non) adherence 59 100
Prescribing decision making 90 100
Provider risk communication 77 100
Side effects: hot flashes 40 100
Perceived (non) adherence 36 95
side effects: joint/bone pain 42 95
risk of recurrence 41 90
Perceived reasons for (non) initiation 60 80
compelling arguments 17 75
risk of side effects 36 75
side effects: other 20 55
side effects: sexual function 14 50
Double-edged sword 14 45
informational materials 15 45
rare complications 9 45
side effects: overwhelming 9 45
research gap and recommendations 10 40
information seeking 9 35
Beliefs in line with behavior 9 30
Fertility 6 30
reminders 9 30
side effects: mood 7 30
Age-based decision making 8 25
Provider frustrations 5 25
Provider dismissiveness 9 20
shared decision making 6 20
side effects: cosmetic 4 20
side effects: cognition 4 15
Fear 2 10
interventions 3 10
no-brainer 2 10
side effects: weight gain 3 10
comorbid conditions 2 5
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ET in greater detail closer to the time the patient is ready to 
take ET. As these physicians explained:
We end up talking about it [ET] several times. … I mention 
it in the very first consultation … as part of the whole 
package. … We talk about, now that this cancer is out of 
their body, what’s the likelihood that they might have a 
recurrence and how recurrence can happen even if the doctor 
resected it all. … We talk about the biology of recurrence 
and make sure they understand that we’re talking about 
reducing a risk of something happening, but that we don’t 
know that that’s going to happen to them. I set the stage of 
what’s the situation we’re in to help people weigh the risks 
and benefits. … We talk about estrogen receptors, and we 
say ‘OK, for your cancer, we need to use this element and 
that element, and then, down the road, we’re going to use 
this anti-estrogen. We’re going to talk about that later, but 
it’s important that you know about it.’
I always tell my patients the pathology report is one of 
the most important pieces of information. … We’ll actu-
ally go through it, and I’ll draw the receptors on a breast 
cancer cell for patients so they understand how their cancer 
grows. Then I draw an X through it and say, ‘This is what 
the drug is going to do,’ to really hit them over the head 
with how important this therapy is. If they’re estrogen 
receptor-positive, we’re having that conversation at their 
very first visit. Whether they remember it is another ques-
tion … but I try to make certain it’s a part of the treatment 
algorithm.
What I really try to instill in them upfront is ‘ET is 
really important for you in terms of risk reduction. This 
is not like a 1 percent reduction of risk. This could be 
upwards of 10 or 15 percent risk reduction.’ I always give 
both benefits and risks, and I try to indicate to the patient 
that this is a very safe therapy, but that some what I would 
call nuisance side effects many times make the drug such 
a nuisance that it’s intolerable.
Providers consider eT an integral part 
of active treatment, the most compelling 
argument for which is its value in 
reducing the risk of recurrence
The providers we interviewed said that they present each 
patient’s individual risk of recurrence to her and the potential 
ET has of reducing that risk. Most often, this information is 
presented in “absolute risk” terms because they have found 
that to be the most understandable way for patients to process 
the treatment decision. As these providers described it:
I’ll give them the risk–benefits percentages. In general, 
endocrine therapy will decrease the risk of the cancer com-
ing back by 40 percent. So I will talk to them about that 
and about how the risk factors of the medicine may be less 
than 5 percent. If they still want to make the choice not to 
take it, it’s their choice. I’ll respect that. But I usually go 
over the benefit of the medicine a few times to make sure 
they really understand. … I’ve learned to use the analogy 
of ‘There are 100 women [just like you] sitting in the room, 
and 40 of them are going to have their cancer come back. 
And if those 40 take [ET] then only 20 to 24 of them will 
have it come back.’ They can actually envision people 
sitting in a room.
Since Americans are notoriously terrible at math, 
I use absolute numbers. I’ll say, ‘If I had 100 women like 
you in a room and we did this and that, this is what would 
happen. And if [these 100 women] took these pills, we 
would save this many people in that room and prevent a 
lot of relapses.’
Some providers described a more nuanced communication 
and decision-making process around risk–benefit trade-offs:
In the adjuvant setting, it is all about weighing the risks and 
benefits. So it’s very important for the oncologist to try to 
accurately quantify the risk of recurrent breast cancer if we do 
nothing in terms of therapy and also to make sure the patient 
understands what we are talking about when we talk about 
recurrence. We’re not just talking about another lump in the 
breast. We’re talking about the likelihood that there’s a rogue 
cell that could come back as a metastasis in your liver. So if 
we take no therapy at all, is that risk 40 percent or 4 percent? 
And then your net gain from using ET is weighed depending 
on how high-risk your disease is to begin with. … I try to give 
patients an adequate sense of what we are gaining and what 
we are losing if we take an ET. For example, if someone is 
90 or 75 with a multitude of other medical problems and has 
a stage one, small node-negative, estrogen receptor positive 
breast cancer and you crunch those numbers, the risk of a 
recurrence over the next five to 10 years might be something 
like 15 percent. Her risk of dying from something else on her 
medicine list might be higher than that. Adjuvant endocrine 
therapy probably would reduce her risk of recurrence by about 
5 or 6 percentage points. You and she might decide that’s 
simply not worth having to take another pill or worth the 
risk of fracture or hot flashes. … You have this very balanced 
discussion and say, ‘Well, you know, 2 percent of women 
have blood clots and 1 percent have uterine cancer, and I think 
your net gain from Tamoxifen might be 3½ percent.’ And 
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they might say, ‘OK, thank you very much. I’m not going to 
take that,’ … because it might be sort of a gray area where 
the odds don’t [justify it]. … We joke that … the length of 
the consultation increases as the size of the tumor decreases. 
It’s easy if there’s a high-risk cancer and you and the patient 
both want to treat it with everything.
All of the providers reported that they emphasize to their 
patients the potential long-term value of ET. In fact, many 
cited research that has shown ET to be more important than 
chemotherapy in preventing recurrences. Some of the pro-
viders elaborated on the importance of ET relative to other 
treatments:
I tell patients that ET is more important than chemotherapy 
because the absolute benefit you derive from chemotherapy 
is anywhere from 2 to 7 percent, depending on the 
biology of your cancer, whereas Tamoxifen reduces your 
risk of recurrence usually on the order of 40 to 50 percent, 
and it reduces the risk of contralateral new breast cancer 
by 50 percent.
[I tell the patient] that proportional benefits [of ET] [are] 
higher than you would actually receive from chemotherapy, 
which is one-third proportional reduction. I remember hav-
ing multiple conversations with a patient who preferred 
chemotherapy over endocrine therapy. I tried to explain 
that the margin of benefit is actually lower for the chemo 
than endocrine therapy alone. Many patients’ risks are 
so high we need to combine everything we possibly can: 
chemotherapy, endocrine therapy, and the like. But when 
you’re really talking about the proportional benefit, the 
endocrine therapy has a much higher proportional benefit 
than chemo itself.
Providers base their decision of which 
eT to use on the patient’s menopausal 
status, percent of estrogen positivity, 
comorbidities, and risk factors
Providers noted they first take into account menopausal 
status to determine which ET to provide. Generally speak-
ing, premenopausal, HR+ females are candidates for 
tamoxifen, while postmenopausal females are candidates 
for an AI. Those who are premenopausal and later become 
postmenopausal use a combination of the two. Other factors 
that affect their choice of therapies are females’ comorbid 
medical conditions and risk factors. For example, females 
with a history or predisposition toward thrombosis would 
not be good candidates for tamoxifen, while an AI would 
not be advisable for females with severe osteoporosis. In the 
rare cases where females have risk factors for both kinds of 
therapy, or who are elderly and frail, providers explained they 
may not recommend ET at all if their degree of cancer risk 
is low. Generally, postmenopausal patients receive 5 years 
of treatment with an AI. Since the Atlas study, the trend 
among these providers regarding tamoxifen is to move toward 
10 years of treatment.12 Some of the providers explained their 
prescribing decisions this way:
The main determinant is menopausal status. In premeno-
pausal women, I don’t use an AI. With a patient who has 
osteoporosis, I may not start with an AI. Conversely, with a 
patient with a deep vein thrombosis (DVT) or thrombolytic 
history, I wouldn’t like to start with Tamoxifen. So those 
are the main comorbidities that I take into account. Patients 
who have a lot of trouble with musculoskeletal systems are 
sometimes leery of AIs, at least initially.
In the pre-menopausal category, my therapy of choice 
is Tamoxifen, unless a patient has a predisposition for 
blood clotting, history of DVTs … or some other medical 
reason to steer clear of Tamoxifen based on their clotting 
risk or endometrial pathology. If I have a patient with a 
medical contra-indication to Tamoxifen, I pursue ovar-
ian oppression … so I can medically place a patient in 
menopause. … And then I would prescribe an aromatase 
inhibitor with ovarian suppression because I’ve made them 
chemically post-menopausal. Then, nine times out of 10, I 
start with an aromatase inhibitor. … I’ve followed the lead 
of five years of the aromatase inhibitor. You could select 
a steroidal (Aromasin or Exemestane) or non-steroidal 
(Anastrozole or Arimidex). The head-to-head comparison 
showed no long-term difference in efficacy, [but] there 
were differences in the toxicity profiles. … The steroidal 
had a slightly reduced risk of osteoporosis. My aromatase 
inhibitor of choice is Letrozole upfront … based on how I 
was trained and the first drugs that came onto the market. 
… But I’m keen to switch patients over to Aromasin if they 
have arthralgias and myalgias, because I find that some 
patients who don’t tolerate Letrozole or Arimidex will very 
likely tolerate Aromasin.
Providers believed that noninitiation of eT 
is rarely a problem; in fact, they reported 
that the vast majority of their patients 
are extremely receptive to the concept 
of taking eT
All of the providers we interviewed indicated that the vast 
majority of their patients (approximately 90%–95%) are very 
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receptive to the idea of taking ET. They said that only a few 
choose not to initiate this therapy. According to those inter-
viewed, their patients generally view ET positively because 
of the comfort and reassurance of being able to do something 
else to prevent recurrence after chemo and/or radiation. As 
these providers explained:
I find that when patients are taking that pill, they feel more 
reassured they’re fighting their cancer every day. … It’s a 
bit of reassurance that they’re doing everything that they 
possibly can to prevent breast cancer recurrence.
I think they come highly motivated. This is the scare 
of their life for many people, and they’ve all seen a friend 
or family member die [of cancer]. Most women come to it 
saying, ‘What can I do?’ And frankly, if they don’t have 
to have chemo or if they’ve already gotten through chemo, 
endocrine therapy is relatively easy. It’s not a sell job in 
most cases.
Providers reported that they believe that the handful 
of patients who reject ET from the outset generally do so 
because of: fear of side effects and risks; negative feedback 
about ET from friends or on the Internet; reluctance to use 
“any” drug long-term, especially one that would impact their 
endocrine system; incompatible fertility intentions; distrust 
or skepticism of Western medicine; preponderance toward 
holistic or alternative medicine to prevent recurrence in lieu 
of ET; or an inability to function adequately or organize their 
lives. Almost all of the providers reported that in the current 
era, financial considerations are rarely a barrier because of 
the availability of generics. Some of the providers painted 
a picture of their patients who have refused to try ET in the 
following ways:
I certainly do have a handful of patients who [do not initiate] 
due to social constraints, financial constraints, or their own 
inability to organize their lives. Financial constraints have 
become much less of a barrier [over time] in my clinic.
Usually they’ve heard something terrible about the 
medicine from either the Internet or from people they know 
who have taken the medicine, or they just have the feel-
ing that they don’t want to block hormones in their body. 
They just have a constitutional idea that they’re not going 
to do it no matter what. And especially with Tamoxifen, 
they’ve heard about a lot of side effects, so they decide 
not to take it.
Sometimes patients don’t like taking medications at all 
or they read on the Internet that it’s better to take Ginkgo 
biloba than to take Western medicines. … And some 
patients make a thoughtful decision that they just don’t 
want to. If they’re 85 years old, they may say, … ‘I just 
decided I don’t want to add another medicine to my pile.’
Sometimes they come with the preexisting decision 
that they’re not going to do this. In those cases I feel like 
my job is to present them with the information about why 
we use this medication and why and how much it might 
help and then to allow them to make their own decision. 
I think as long as somebody’s competent and they’ve 
heard and understood, it’s not really my job to beat them 
up. … But if the patient has an extremely high-risk cancer 
and it’s strongly ER positive, you know she needs to take 
this drug. Then I do try to motivate [her]. Typically what 
we do is we have them give it a try and then have a short 
interval follow-up. And I try to see what the barriers are. 
We try to get at the ‘what can we work on to make this drug 
work for you?’ Sometimes you get there, and sometimes 
you don’t.
Providers believed that adherence and 
persistence were much more problematic 
with eT than noninitiation, mostly because 
of intolerable, unresolvable side effects
According to the providers, some of their patients who were 
motivated to take ET discontinued it because of intoler-
able and unmanageable side effects that severely impacted 
the quality of their lives. Providers reported perceived harms 
of tamoxifen to be: hot flashes that interfere with sleep 
and daily life (the most common complaint); weight gain 
(perceived by females, though not supported by research); 
depression; loss of libido and loss of sexual interest; vaginal 
dryness, vaginal atrophy, and perineal pain; and, much less 
often, frequent urinary tract infections (UTIs), blood clots, 
and other rare events.
Providers reported the perceived harms of AIs to be: arth-
ralgia and myalgia, especially joint pain (the No 1 complaint); 
weakening of the bones (osteoporosis); and less often, loss 
of libido, loss of sexual interest, vaginal dryness, atrophy, 
and perineal pain.
If, in spite of efforts to reduce them, severe side effects 
continue to impact quality of life, some females choose to 
discontinue ET, and the providers typically respect that 
decision. One provider described her experience with non-
adherers this way:
Some people have had such severe joint pain and their risk 
has been low enough and they’ve tried one or two drugs. 
I had an elderly woman who said, ‘I can’t live my life like 
this. I just can’t do this.’ You have to be respectful … and 
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they’re equally respectful. They appreciate that you’re 
making your best medical recommendation. It is all about 
balance and quality of life.
Providers reported using several 
pharmacological and nonpharmacological 
approaches to help females deal with 
the side effects of eT and better support 
females taking eT
Providers help patients manage ET side effects (eg, hot 
flashes and joint pain) with a variety of nonpharmacologi-
cal and pharmacological methods. To deal with hot flashes, 
providers first recommend females try layering clothes, 
using fans, avoiding caffeine and spicy foods, reducing 
their alcohol intake, pursuing a healthy diet and exercise, 
and using progressive relaxation, other mindfulness tech-
niques, and acupuncture. If necessary, they also prescribe 
medications such as venlafaxine, gabapentin or clonidine. 
Most of the providers also screen for depression. For vaginal 
dryness, they typically recommend lubricants or lidocaine 
for intercourse.
Often there is nothing providers can do to make the joint 
pain tolerable other than switching to another drug in the 
class to see whether it is better tolerated. Providers try to 
lessen the joint pain by recommending over the counter pain 
relievers, exercise, vitamin D, yoga, tai chi, and acupuncture, 
with varying success. Some report success with acupuncture, 
although providers noted that acupuncture can be expensive 
and may not be covered by insurance. One provider said her 
hospital offered free acupuncture. Providers describe these 
strategies:
We spend the bulk of the survivorship care for people who 
are on anti-estrogen therapy or who have gone through 
chemotherapy-induced menopause managing side effects. 
There’s a whole litany of things you can do for hot flashes. 
We are screening for depression and anxiety at every visit. 
We’re checking vitamin D levels, and we spend a lot of 
time talking about arthralgia. The nurse navigators field 
a lot of calls about symptoms as well and try to strategize 
with the women – everything from common sense, ‘wear 
layers,’ to vitamin E to gabapentin.
The AI’s are tough. It’s the joint pains and muscle 
aches. What the patients basically say is ‘I feel like I’m a 
hundred years old.’ It’s worse in the morning for a lot of 
these patients. There are some studies that show yoga can be 
helpful. … There’s some minor data that people with lower 
vitamin D [have more joint pain]. … Adding vitamin D 
can make it tolerable, and that’s what you’re looking for. 
If it’s that uncomfortable, you can switch to another AI, 
which they may tolerate better. … I think a small number 
actually stop … though more may become more erratic in 
taking it or not. … Their fear of the risk of recurrence is a 
big motivator.
Discussion
Because ET is a vital component of active treatment for 
HR+ females and ET initiation, adherence, and persistence 
are known to be suboptimal, the perspectives of providers 
managing these patients are critical to understanding the 
challenges and opportunities involved in optimizing care 
for this patient population. Our in-depth interviews sug-
gest that providers recommend ET in a consistent manner, 
and while these providers believed that ET noninitiation 
is rare, ET nonadherence was cited as a major source of 
concern for the management of HR+ breast cancer patients. 
In particular, persistent side effects were believed to be a 
major contributor to nonadherence, and providers expressed 
encountering significant challenges managing these side 
effects due to heterogeneity in patient experience, and 
limited options and evidence for successfully managing 
side effects. Thus, while many of the other barriers may be 
important, side effect management in particular should be a 
priority for research into improved side effect management 
and for health services/comparative effectiveness research 
to identify best practices and disseminate this knowledge to 
providers. Overall, providers discussed the important role 
of risk communication as a motivating factor for both ET 
initiation and adherence. In particular, providers discussed 
the advantages for discussing risk in absolute rather than 
relative terms with patients.
Nonadherence was primarily associated with persistent 
and unmanageable side effects from ET, primarily hot flashes, 
night sweats, and joint pain. This aligns with literature asso-
ciating high side effect burden with ET nonadherence.2,13,14 
Other barriers associated with ET adherence have been 
presented in the literature, such as minority race/ethnicity,13 
cost, poor patient–provider communication, and others.2,14,15 
However, these factors were discussed less often by provid-
ers, perhaps because side effects are the most significant 
barriers that patients experience and discuss with their 
providers.15 Oncology training and practice tend to emphasize 
disease treatment guidelines, not guidelines for management 
of side effects of treatment, which represents an understudied 
area that is important to improving patient outcomes and 
quality of life.
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Most providers felt that the majority of their patients 
were willing to try ET and that noninitiation was rarely 
a concern. They believed most patients agreed with the 
premise of ET in terms of its efficacy in reducing recurrence 
risk. Patient data from other settings, however, suggest 
that noninitiation may be prevalent, most often for females 
of lower socioeconomic16 status or minority race or older 
age.14,17 Providers from this study associated noninitiation 
with patient distrust of conventional medicine. Patient-
reported reasons for noninitiation should be further explored 
in future work. In some cases, providers may not even 
know that their patients never initiated therapy. Accord-
ingly, research is also needed that explores patient–provider 
communication about medication taking behavior after 
prescriptions are written.
Our data point to several takeaways for practicing oncol-
ogy providers, including: to more effectively communicate 
ET risks and benefits, particularly emphasizing the role 
of ET in reducing risk of recurrence, and help patients to 
adequately cope with and tolerate ET in light of significant 
and sometimes debilitating side effects. These suggestions 
require thoughtful implementation in order to be realized 
most optimally, since 1) the clinic environment can be quite 
busy and individual visits with oncology care providers are 
shorter than ideal; 2) a one-size-fits-all strategy will not 
be appropriate for risk communication or for side effect 
management; and 3) messaging must be continual and 
consistent to help support ET adherence and persistence for 
5–10 years, as recommended. Strategies to address these 
challenges may include using more lay or peer navigators 
in the clinic (who can afford to spend more time with each 
individual patient),18,19 tailoring risk communication20 and 
side effects management to better fit with the individual 
patient’s experience,21,22 and consolidating evidence-based 
information about effective management of ET-related side 
effects, including pharmacological and nonpharmacological 
options.22
While previous studies have examined the barriers and 
facilitators for ET use among certain subgroups of breast 
cancer patients,23,24 this study, to our knowledge, is the first 
qualitative study to examine providers’ perspectives on ET 
prescribing, initiation, and adherence. These perspectives are 
essential in understanding the key barriers and facilitators for 
the use of ET among breast cancer patients. Furthermore, 
to promote shared decision making regarding ET use, it 
is essential that both patients and providers have a shared 
understanding about these key barriers and facilitators of 
ET use. Patients in prior studies23,24 and providers in our 
study primarily discussed suboptimal symptom management 
as the main barrier for ET use. But evidence suggests that 
females often do not feel empowered to discuss symptom 
management with their providers and even when they do 
raise the issue, symptoms are not always easily addressible.23 
Furthermore, patients have previously reported not know-
ing that missing ET doses could reduce the medication’s 
efficacy.23 So, while both patients and providers agree that 
symptom management is important, there seems to be a dis-
connect in the delivery of symptom management strategies 
to patients in need.
Limitations
Some limitations of this study require careful acknowledge-
ment. While we interviewed providers across geographic 
regions, health care settings, and patient-care roles, these 
provider perspectives may not be generalizable to providers 
who did not opt to participate in the study. It is possible that 
providers we interviewed who felt that certain issues were not 
relevant (eg, noninitiation) may have simply been reflecting 
the experiences of their own panel of patients, which may 
not be representative of all patients’ and providers’ experi-
ences. Despite these limitations, we believe our internal 
validity was high; we spent considerable time developing 
and revisiting the codebook, discussing code application in 
detail when questions emerged during the coding process, 
and assessing code consistency and reliability on a subset of 
transcripts. Additionally, we achieved saturation of themes 
in our 20 interviews.
Conclusion
This study identifies priority areas for engaging providers 
to help improve ET adherence among females with HR+ 
breast cancer. Specifically, side effects from ET treatments 
represent the dominant factor in nonadherence, and evi-
dence suggests that some patients experience considerable 
difficulty managing such symptoms. Efforts to manage the 
most troublesome symptoms may fail because of the limited 
number of effective management strategies currently avail-
able. Efforts to improve adherence should focus on provider-
directed strategies to prepare patients for and help minimize 
side effects, empower patients to seek help when side effects 
become unmanageable, and ensure that both clinicians and 
patients are educated about and continue to discuss optimal 
side effect management as problems emerge. This finding has 
important implications for the management of HR+ breast 
cancer patients, especially as evidence points to ET regimens 
that extend beyond 5 years.
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